Patent EA-004738-B1 (EA)
Title: New cyclobutaindolecarboxamide compounds, a process for their preparation and pharmaceutical compositions containing them
Inventor: PEGLION JEAN-LOUIS
IPC: A61P25/00
Filed: 2001-04-12
Abstract: 1. Compounds of formula (I): wherein: n represents an integer of from 0 to 6, R1 represents a group selected from hydrogen, hydroxy, cyano, and NR4R5 wherein R4 and R5, which may be identical or different, represent a linear or branched (C1-C6)alkyl, R2 represents a group selected from hydrogen or a group of formula and -U-V-W wherein: * T represents a monocyclic or polycyclic (C3-C12)cycloalkyl group, * U represents a bond, * V represents a bond, an oxygen atom or a group S(O)q wherein q is 0, and * W represents a group selected from phenyl and cycloalkyl, and R3 represents pyridyl optionally being substituted by one or more identical or different groups selected from C1-C6alkyl and pyridyloxy optionally substituted by C1-C6alkyl, their isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. 2. Compounds of formula (I) according to claim 1, characterised in that R2 represents a hydrogen atom, their isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. 3. Compounds of formula (I) according to claim 1, characterised in that R2 represents a group of formula wherein T is as defined for formula (I), n is 1, and R1 represents a cyano group or an amino group optionally substituted by one or two identical or different groups selected from linear or branched C1-C6alkyl groups, their isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. 4. Compounds of formula (I) according to claim 1, characterised in that n is 0, R1 represents a hydrogen atom or a cyano group and R2 represents a hydrogen atom, their isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. 5. Compounds of formula (I) according to claim 1, characterised in that n is 0, R1 represents a hydrogen atom or a cyano group and R2 represents a group of formula -U-V-W wherein U represents a single bond, V represents a group of formula S(O)q wherein q is as defined for formula (I) and W represents a phenyl group, their isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. 6. Compounds of formula (I) according to claim 1 that are: -N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -5-cyano-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -6-cyano-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -6-(hydroxymethyl)-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -5-(hydroxymethyl)-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -7-cyano-N-(3-pyridyl)-1,2,6,7-tetrahydro-3H-cyclobuta[e]indole-3-carboxamide, -7-(hydroxymethyl)-N-(3-pyridyl)-2,3,6,7-tetrahydro-1H-cyclobuta[g]indole-1-carboxamide, -6-[(dimethylamino)methyl]-6-(1-hydroxycyclohexyl)-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -6-cyano-6-(phenylsulphanyl)-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -6-cyano-6-cyclohexyl-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -6-cyclohexyl-N-(3-pyridyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, -6-cyano-N-{6-[(2-methyl-3-pyridyl)oxy]-3-pyridyl}-6-(phenylsulphanyl)-2,3,5,6-tetrahydro-1H-cyclobuta[f]indole-1-carboxamide, their isomers, and also addition salts thereof with a pharmaceutically acceptable acid or base. 7. A Pharmaceutical composition for use in the treatment of anxiety, panic attacks, obsessive-compulsive disorders, phobias, impulsive disorders, drug abuse, cognitive disorders, psychoses, depression and mood disorders containing at least one active ingredient according to any one of claims 1 to 6 for use in the treatment of anxiety, panic attacks, obsessive-compulsive disorders, phobias, impulsive disorders, drug abuse, cognitive disorders, psychoses, depression and mood disorders, alone or in combination with one or more pharmaceutically acceptable, inert, non-toxic excipients or carriers.